**Core tip:** Aberrant up- or downregulation of homeobox genes may play pivotal roles in the development and progression of gastrointestinal (GI) cancers. Core research in GI cancers has focused on non-HOX genes including caudal-related homeobox transcription factor 2. However, recent studies have demonstrated significant functions of specific *HOX* genes, including *HOXB7*, *HOXA13*, and *HOXD10*, in GI cancers. Here, we review the major research data concerning the deregulation of homeobox genes in GI cancers and their underlying mechanisms.

INTRODUCTION
============

The homeobox genes were first discovered in *Drosophila melanogaster* where their mutation led to malformations of body parts\[[@B1]\]. As the name implies, homeobox genes play crucial roles in the development of the embryo along the anterior-posterior axis. The human genome contains about 235 functional homeobox genes, most of which are dispersed throughout the genome and contain a highly conserved 180 nucleotide sequence (homeobox) encoding 60 amino acids along the DNA-binding protein domain (homeodomain)\[[@B2]\]. A typical characteristic of the homeodomain is its DNA-binding nature; it functions as a transcription factor by binding to the promoter of various target genes. Several cofactors, such as pre-B-cell leukemia transcription factor 2 (PBX2) or myeloid ecotropic viral integration site (MEIS), interact with homeobox genes to form a protein complex and facilitate the specificity and stability of homeobox genes by binding to promoter DNA\[[@B3]\].

Homeobox genes are generally classified as class I (*HOX*) and class II (non-*HOX*). In humans, 39 *HOX* genes have been identified. They cluster into 4 groups named A, B, C, and D, located in 7p15.3, 17q21.3, 12q13.1, and 2q31, respectively\[[@B4]\]. Each HOX gene in a cluster is arranged from the 3' to 5′ end and named from 1 to 13. HOX genes located at the 3′ end are expressed early in development and in anterior tissues, while HOX genes at the 5′ end are expressed later and in posterior tissues\[[@B5]\].

Numerous studies have revealed that various homeobox genes have either tumor-suppressive or tumor-promoting effects according to their aberrant expression patterns in certain organs. In terms of their oncogenetic properties, homeobox genes are normally expressed during the embryonic period and are reactivated in tumors, while being downregulated in normal differentiated adult tissues. In contrast, certain homeobox genes are expressed in normal differentiated adult tissues, but are downregulated in tumors\[[@B1]\]. This aberrant reduced or enhanced expression of homeobox genes is regulated by several mechanisms, such as loss of heterozygosity, gene amplification, CpG island promoter hypermethylation, or histone deacetylation, and consequently contributes to the development and progression of cancer.

Interestingly, a homeobox gene may have both tumor-promoting and tumor-suppressing properties depending on the specific organs or cell lineages where it is expressed. For example, HOXA9 is downregulated in lung cancer tissues compared to that in surrounding non-cancerous tissues by an epigenetic silencing mechanism, whereas it is upregulated in acute lymphocystic leukemia\[[@B6],[@B7]\]. HOXB13 is another example that is upregulated in breast cancer but downregulated in prostate cancer compared to surrounding normal tissues\[[@B8],[@B9]\]. Several long and short non-coding RNAs are also involved in the regulation of transcription or expression of homeobox genes. For example, *HOX* transcript antisense intergenic RNA (HOTAIR), a long non-coding RNA, is located in the *HOXC* locus near the 5′ end, and recruits polycomb repressive complex 2 to lead epigenetic silencing of the *HOXD* locus\[[@B10]\]. MicroRNAs (miRNAs), including miR-10a, miR-10b, miR-196a, and miR-196b, are also located within the HOX clusters and target multiple *HOX* genes to regulate their expression post-transcriptionally\[[@B4]\]. Therefore, it is important to understand the aberrant expression pattern of homeobox genes in specific cancer types or cell lineages, and their underlying mechanisms for carcinogenesis and invasion of certain types of cancer.

In this editorial, we summarize the outcomes of previous studies of homeobox genes that showed valid influences on solid tumors in the gastrointestinal (GI) tract, including esophageal, gastric, and colorectal cancers (CRCs). This article provides information on the underlying molecular mechanisms, aberrant expression in GI cancer tissues, and the potential value of various homeobox genes for early recognition or prediction of prognosis in GI cancers.

ESOPHAGEAL CANCER
=================

Most studies of homeobox genes in Barrett's esophagus (BE) and esophageal adenocarcinoma (EAC) have focused on non-*HOX* genes, especially caudal-related homeobox transcription factor 2 (CDX2). Generally, acid and bile reflux at the esophagogastric junction promotes dedifferentiation of the basal layer of the esophageal squamous epithelium. This is where secretion of CDX2 is increased, and morphogenic and metaplastic changes occur, eventually leading to the development of intestinal-type squamous to columnar metaplasia\[[@B11]\]. Indeed, CDX2 plays a crucial role in the development of BE, a major precursor of EAC. In addition, several previous studies showed that mRNA and protein expression of CDX2 was increased significantly in BE and EAC compared to normal esophageal tissues, although no significant difference could be found between BE and EAC\[[@B12],[@B13]\]. The expression of CDX2 protein was well-conserved in an EAC cell line, but was not detected in esophageal squamous cell carcinoma (ESCC) cells. Furthermore, demethylation or exposure of esophageal squamous epithelial cells to acid or bile induced CDX2 as well as other intestinal markers. These findings suggested that CDX2 is a key modulator of intestinal metaplasia of esophageal squamous cells in response to acid or bile reflux\[[@B14]\]. In terms of *HOX* genes, a previous well-designed study showed that mid-cluster *HOXB* genes (*HOXB5*, *B6*, and *B7*) were upregulated in BE tissue as well as in dysplasia and EAC. However, no significant difference was observed between BE with dysplasia and EAC. Furthermore, these mid-cluster *HOXB* genes induced several intestinal markers including KRT20, Muc2, and villin in esophageal cells in a CDX2-independent manner\[[@B15]\].

A previous study using the reverse transcriptase-polymerase chain reaction (RT-PCR) showed that *HOXA7*, *A9*, and *C6* mRNAs were overexpressed significantly in ESCC tissues compared to non-cancerous surrounding tissues\[[@B16]\]. A microarray study showed that the mRNA expression of several *HOX* genes, including *HOXA5, A10, B13, C6, C10, C13*, and *D3*, was upregulated significantly in ESCC tissues compared to normal esophageal mucosa, and these genes were differentially expressed according to the T stage; expression was the highest in T2\[[@B17]\]. This study also showed that several non-*HOX* genes, including *CDX1* and *CDX2*, were expressed at higher levels in ESCC than normal esophageal mucosa. However, another crucial study demonstrated that most of the expression of CDX2 in ESCC cell lines and tissues was governed by an epigenetic silencing mechanism that was not found in EAC, CRC, or normal esophageal tissues\[[@B18]\]. This suggested that aberrant inactivation of CDX2 is an important step toward the development of ESCC.

Among the *HOX* genes, *HOXA13* has been most actively investigated in ESCC. A previous pivotal study very nicely showed the tumorigenic effect of HOXA13 *in vivo*, and that there was a significant association between HOXA13 and both median and disease-free survival\[[@B19]\]. Chen and his colleagues, using knockdown of HOXA13 in ESCC cell lines and 2-dimmensional electrophoresis, suggested that annexinA2, manganese superoxide dismutase (MnSOD) and endoplasmic reticulum-associated amyloid β-binding protein (ERAB) were crucial target genes of HOXA13\[[@B20]\]. These researchers also used ESCC tissues to show that co-expression of HOXA13 with annexinA2 and SOD was significantly associated with poor prognosis\[[@B21]\]. Other *HOX* genes, such as *HOXA9* and *B7*, were also upregulated in ESCC at advanced T or N stages, and in patients with poor prognosis\[[@B22],[@B23]\]. Meanwhile, a recent study demonstrated that *MEIS1*, a non-*HOX* homeobox gene, was downregulated in ESCC patients and was associated inversely with advanced TNM stage. The mechanism was thought to be mediated by upregulation of SRY (sex determining region Y)-box 2 (SOX2) in ESCC cells\[[@B24]\] (Table [1](#T1){ref-type="table"}).

###### 

Aberrant expression of *HOX* and non-*HOX* genes in esophageal cancer

  **Homeobox gene**                       **Change**                                                            **Underlying mechanism**                                         **Ref**.
  --------------------------------------- --------------------------------------------------------------------- ---------------------------------------------------------------- -----------
  BE/EAC                                                                                                                                                                         
  *CDX2*                                  ↑ in BE/EAC                                                           Concomitant decrease of PITX1                                    \[12,13\]
  No difference between BE and EAC        Association with β-catenin                                                                                                             
  *HOXB5, B6, B7*                         ↑ in BE/dysplasia/EAC                                                 Induction of intestinal markers such as KRT20, Muc2 and villin   \[15\]
  ESCC                                                                                                                                                                           
  *CDX2*                                  ↓ in a ESCC cell line and tissues                                     Promoter hypermethylation                                        \[18\]
  *MEIS*                                  ↓ in ESCC, inversely related with nodal status and high tumor stage   Concomitant increase of SOX2                                     \[24\]
  *HOXA7, A9, C6*                         ↑ in ESCC                                                             Not presented                                                    \[16\]
  *HOXA5, A10, B13, C6*, *C10, C13, D3*   ↑ in BE/EAC, highest in T2 stage                                      Not presented                                                    \[17\]
  *HOXA13*                                ↑ in ESCC, associated with OS and DFS                                 Targeting annexinA2, MnSOD, ERAB                                 \[19-21\]
  *HOXB7*                                 ↑ in ESCC, associated with T/N stage and DFS                          Not presented                                                    \[23\]

BE: Barrett's esophagus; EAC: Esophageal adenocarcinoma; ESCC: Esophageal squamous cell carcinoma; MnSOD: Manganese superoxide dismutase; OS: Overall survival; DFS: Disease free survival.

STOMACH CANCER
==============

The most extensively researched homeobox genes in stomach cancer are *CDX2* and *CDX1*. These genes are closely involved in the development of intestinal metaplasia of the gastric mucosa. A previous pivotal study demonstrated the causal role of CDX2 in the development of intestinal metaplasia in the stomach by using a *Cdx2*-expressing transgenic mouse model\[[@B25]\]. The *Cdx1* transgenic mouse also exhibited significant intestinal metaplasia, although the characteristics were somewhat different from the *Cdx2* transgenic mouse; the former replaced the gastric mucosa with intestinal metaplasia involving all four intestinal epithelial cell types (absorptive enterocytes, goblet, enteroendocrine, and Paneth cells), whereas only pseudopyloric gland metaplasia was observed in the *Cdx2* transgenic mouse\[[@B26]\]. This phenomenon suggested that a different mechanism and roles between CDX1 and CDX2 may exist in the differentiation of intestinal metaplasia.

In human stomach, ectopic expression of CDX1 and CDX2 was observed frequently in intestinal metaplasia tissues. However, only CDX2 was an independent factor of intestinal type gastric adenocarcinoma\[[@B27]\]. Another study showed that the expression of CDX2 in gastric cancer was governed mainly by promoter hypermethylation. This suggested that aberrant downregulation of CDX2 might promote gastric carcinogenesis\[[@B28]\]. Liu et al\[[@B29]\] suggested that CDX2 was associated mainly with the formation of intestinal metaplasia of gastric mucosa, and was less involved in dysplasia and cancer, by demonstrating that the expression of CDX2 protein was highest in complete type intestinal metaplasia, followed by incomplete intestinal metaplasia, dysplasia, and the lowest in gastric cancer tissues. The exact molecular characteristics of CDX2 in the development of intestinal metaplasia and gastric cancer should be further evaluated. Indeed, the unique characteristics of CDX2 are associated with both oncogenic and tumor-suppressive functions, and these ambivalent roles of CDX2 might be tissue- or site-specific. At present, CDX2 appears to be involved in the initiation of the process leading to intestinal type gastric neoplasia such as induction of intestinal metaplasia\[[@B30]\].

Several other non-*HOX* homeobox genes, including intestine-specific homeobox (*ISX*), prospero homeobox 1 (*PROX1*), paired-related homeobox 1 (*PRRX1*), iroquois-class homeodomain (*IRX1*), and pancreatic-duodenal homeobox 1 (*PDX1*), have been investigated for their relationship with intestinal metaplasia and gastric cancer. Among these genes, *ISX*, *PROX1*, and *PRRX1* were associated with the promotion of gastric cancer, suggesting their oncogenetic roles\[[@B31]-[@B33]\]. Specifically, ISX was upregulated in intestinal metaplasia and its levels correlated significantly with CDX2 expression in mice with chronic *Helicobacter felis* infections. However, ISX also enhanced cyclin D1 (a G1 → S cell cycle modulator) and CD44 (a stem cell marker of gastric cancer) expression, and its protein expression was increased significantly in undifferentiated-type gastric cancer, unlike CDX2\[[@B31]\]. PROX1 promoted cellular proliferation, angiogenesis, and epithelial-mesenchymal transition (EMT) *in vitro*. Furthermore, its tissue expression was significantly associated with advanced stage, undifferentiated type, lymph node metastasis, and poor prognosis\[[@B32]\]. PRRX1 also showed EMT-promoting functions *via* inducing the Wnt/β-catenin pathway, and was significantly associated with advanced-stage and distant metastasis\[[@B33]\]. In contrast, several *in vitro* studies showed that the expression of IRX1 and PDX1 mRNA was downregulated in gastric cancer cells by an epigenetic silencing mechanism *via* promoter hypermethylation, suggesting their tumor-suppressive functions\[[@B34]-[@B36]\]. Another study demonstrated that PDX1 expression was associated with the pseudopyloric gland of intestinal metaplasia tissues, and was decreased in patients with advanced stage and lymph node metastasis, compared to early stage gastric cancer\[[@B37]\]. However, a few studies demonstrated a significant relationship between various non-*HOX* homeobox genes and clinicopathological parameters such as TNM stage, differentiation, overall and disease-free survival rate of gastric cancer patients. The nature of this relationship requires further study.

Recently, investigations into the role of *HOX* genes in gastric carcinogenesis and progression have been performed. One notable study used microarray analysis to reveal the global expression patterns of 39 human *HOX* genes among 12 pairs of gastric cancer and non-cancerous tissues. The authors showed that the expression of *HOXA1, A4, A10, A13, B7*, and *C10* was increased significantly in cancer tissues. Among these genes, upregulation of HOXA13 was associated significantly with T stage, M stage, advanced UICC stage, histologic differentiation and relapse. Furthermore, patient with positive HOXA13 expression had a lower overall survival and disease-free survival compared with patients with negative HOXA13 expression. The contribution of HOXA13 towards tumorigenesis and aggressive biologic behavior in gastric cancer might be associated with downregulation of tumor growth factor-β (TGF-β) and its downstream target of Runt-related transcription factor 3 by antagonizing Smad3\[[@B38]\]. Concurrent researches on individual *HOX* genes in gastric cancer have been conducted. An *in vitro* study showed that *HOXB5* promoted migration and invasion of gastric cancer cells by binding directly to the *CTNNB1* promoter and thus activating the Wnt/β-catenin signaling pathway\[[@B39]\]. Another pivotal study showed that HOXD10 mRNA expression was downregulated significantly in stomach cancer tissues compared to normal surrounding tissues. This downregulation was caused by promoter hypermethylation, and the aberrant reduction of HOXD10 expression led to proliferation, migration, invasion, and tumorigenesis in gastric cancer cells\[[@B40]\]. We reported recently that *HOXB7*, one of the most widely investigated oncogenic *HOX* genes, was highly expressed in primary or metastatic gastric cancer tissues compared to chronic gastritis or intestinal metaplasia tissues. This suggested that HOXB7 might be involved in the progression rather than initiation process of gastric cancer\[[@B41]\]. This phenomenon has been validated by *in vitro* studies showing that overexpression of HOXB7 in gastric cancer cells promoted cellular invasion and migration, and inhibited apoptosis, whereas silencing HOXB7 showed the opposite effects\[[@B41],[@B42]\].

The main target of HOXB7, and the mechanism involved in the upregulation of HOXB7 in cancer, are still under controversy. We suggested that HOXB7 regulates Akt/PTEN signaling to induce migration and invasion of gastric cancer cells, by using transient transfection of a HOXB7-expressing plasmid and HOXB7 siRNA. A recent well-designed study demonstrated that HOXB7 promoted the EMT and invasiveness of breast cancer cells by regulating the TGF β2-SMAD3 axis\[[@B43]\]. Several receptor tyrosine kinase signaling pathways, including beta fibroblast growth factor and epidermal growth factor receptor, were also reported to be activated by HOXB7 in breast cancer cells\[[@B44]-[@B46]\]. Thus, HOXB7 might be simultaneously involved in various key molecular signaling pathways involving cancer progression, which supports the potential value of HOXB7 as a promising therapeutic target. Several miRNAs, including miR-196a and miR-196b, were suggested as key regulators of HOXB7 expression in other types of cancer\[[@B47],[@B48]\]. Further investigations to reveal the mechanisms underlying the induction of HOXB7 and its targets in gastric cancer are needed (Table [2](#T2){ref-type="table"}).

###### 

Aberrant expression of *HOX* and non-*HOX* genes in gastric cancer

  **Homeobox gene**                                                                             **Change**                                                       **Underlying mechanism**                                                **Ref**.
  --------------------------------------------------------------------------------------------- ---------------------------------------------------------------- ----------------------------------------------------------------------- --------------
  *CDX2*                                                                                        ↑ in complete IM \> incomplete IM \> dysplasia \> GC             Promoter hypermethylation in GC                                         \[27-29\]
  Associated with differentiated type GC                                                        Decreased intake of green tea or cruciferous vegetables                                                                                  
  *ISX*                                                                                         ↑ in IM and GC                                                   Increase of cyclin D1 and CD44                                          \[31\]
  Upregulated in undifferentiated type GC                                                                                                                                                                                                
  *PROX1*                                                                                       ↑ in GC                                                          Inhibition of apoptosis, promoting lymphangiogenesis and angiogenesis   \[32\]
  Associated with undifferentiated type, advanced stage and poor OS                                                                                                                                                                      
  *PRRX1*                                                                                       ↑ in GC                                                          Induction of Wnt/β-catenin                                              \[33\]
  Associated with advanced stage and distant metastasis                                                                                                                                                                                  
  *IRX1*                                                                                        ↓ in GC                                                          Promoter hypermethylation                                               \[35\]
  *PDX1*                                                                                        ↓ in GC                                                          Promoter hypermethylation, histone hypoacetylation                      \[34,36,37\]
  ↑ in pseudopyloric gland IM                                                                                                                                                                                                            
  Inversely related with advanced T/ N stage and undifferentiated type GC                                                                                                                                                                
  *HOXA13*                                                                                      ↑ in GC                                                          Not presented                                                           \[38\]
  Associated with advanced TNM stage, undifferentiated type and poor response to chemotherapy                                                                                                                                            
  *HOXB5*                                                                                       ↑ in GC                                                          Upregulation of β-catenin                                               \[39\]
  *HOXB7*                                                                                       ↑ in primary or metastatic cancer than chronic gastritis or IM   Modulation of PI3K/Akt/PTEN axis                                        \[41,42\]
  Associated with advanced TNM stage and undifferentiated type GC                                                                                                                                                                        
  *HOXD10*                                                                                      ↓ in GC                                                          Promoter hypermethylation                                               \[40\]
  Induction of IGFBP3                                                                                                                                                                                                                    

Note: PROX1, PRRX1, HOXA13 and HOXB7 are associated with advanced TNM stage, while PDX1 is inversely associated; ISX, PROX1, HOXA13 and HOXB7 are associated with undifferentiated type GC. IM: Intestinal metaplasia; GC: Gastric cancer; OS: Overall survival; PI3K: Phosphatidylinositol-3 kinase; IGFBP3: Insulin like growth factor binding protein 3.

CRC
===

Similar to esophageal and gastric cancer, *HOX* and non-*HOX* homeobox genes have been investigated for their unique roles in the development and progression of CRC. Among these genes, CDX2 in colon cancer cells has been researched extensively and reported to regulate the expression of cell junctional proteins. These proteins include liver-intestine cadherin (LI-cadherin)\[[@B49]\] or protocadherin Mucdhl\[[@B50]\]. Loss of CDX2 in colon cancer cells downregulated Mucdhl, thereby eliminating the latter's inhibition of Wnt/β-catenin activity. Inflammatory cytokines, such as tumor necrosis factor-α, mediated this process (loss of CDX2 and induction of Wnt/β-catenin signaling) in CaCo2 colon cancer cells\[[@B51]\]. Furthermore, significant tumor formation was observed when heterozygous *Cdx*2^+/-^, but not wild-type mice, were treated with the DNA mutagen azosymethane. This indicated that CDX2 had a tumor-suppressive function in CRC\[[@B52]\]. At the tissue level, reduced expression of CDX2 in colorectal adenoma or cancer was associated significantly with right side tumors, poorly differentiated or high-grade carcinomas, advanced stage, poor prognosis, CpG island methylator phenotype, and mismatch repair-deficient tumors\[[@B53]-[@B55]\].

Previous pivotal studies showed that CDX1 inhibited the proliferation of colon cancer cells by regulating the cyclin D1 or β-catenin/T-cell factor (TCF) pathways\[[@B56],[@B57]\], and that tissue expression of CDX1 was increased significantly in adenomatous polyps but abolished in adenocarcinomas. Furthermore, a novel *in vitro* study showed that CDX1 was governed by miR-215 to promote differentiation and inhibit stemness in colon cancer cells\[[@B58]\]. These data suggested that CDX1 might play a crucial role in the transformation of benign adenomas to malignant tumors.

Other types of non-*HOX* homeobox genes have been investigated for their roles in CRC. The expression of the airstaless-like homeobox-4 gene (ALX4) was aberrantly reduced in colorectal dysplasia or adenocarcinoma compared with normal colonic mucosa, through DNA methylation\[[@B59]\]. In addition, PROX1 promoted neoplastic transformation, tumorigenesis, and the EMT *via* induction of the β-catenin/TCF pathway and inhibition of E-cadherin activity\[[@B60],[@B61]\].

Relatively few data concerning *HOX* genes have been presented in terms of CRC compared to other GI cancers. A previous quantitative RT-PCR study showed that the expression of several *HOX* genes, including *HOXA9, B3, B8*, and *B9*, was increased significantly in left side colon cancer tissues compared to surrounding normal tissues. In contrast, the expression of *HOXB2, B13, D1, D3, D4, D8*, and *D12* was significantly decreased\[[@B62]\]. A recent gene microarray and immunohistochemical study showed that the expression of HOXA4 and HOXD10 was significantly increased in CRC tissues compared to that in normal tissues. Furthermore, the expression of these genes was clustered in the crypt bottom rather than the top or middle of the crypt where the stem cell niche was overpopulated\[[@B63]\]. Remarkably, *HOX* genes showed a tendency to be differentially expressed in colon tumors according to their location. Specifically, several *HOX* genes, including *HOXA5, A9, A10*, and *C6*, were expressed at higher levels in the proximal colon, and gradually decreased in the distal colon and rectum. *HOXB13* was an exception that showed the opposite pattern\[[@B64]\]. Previous studies showed that expression pattern of HOXB13 was site-specific, which was mainly confined to prostate, rectum and distal colon\[[@B65]\], and HOXB13 inhibited the β-catenin/TCF signaling pathway as post-translational manner, which was downregulated in colorectal tumors\[[@B66]\].

A previous pivotal study demonstrated the prognostic value of HOXB7 in CRC. Patients in the high HOXB7 CRC group had a poorer prognosis than those in the low HOXB7 group. In addition, the tumorigenic and anti-apoptotic effects of HOXB7 in colon cancer cells were mediated by the phosphatidylinositol-3-kinase/Akt and mitogen-activated protein kinase pathways\[[@B67]\] (Table [3](#T3){ref-type="table"}).

###### 

Aberrant expression of *HOX* and non-*HOX* genes in colorectal cancer

  **Homeobox gene**                                                                                                                   **Change**                                   **Underlying mechanism**                            **Ref**.
  ----------------------------------------------------------------------------------------------------------------------------------- -------------------------------------------- --------------------------------------------------- --------------
  *CDX1*                                                                                                                              ↑ in adenomatous polyp, ↓ in CRC             Regulation of cyclin D1 and β-catenin/TCF pathway   \[55,56,58\]
  Regulated by miR-215                                                                                                                                                                                                                 
  *CDX2*                                                                                                                              ↓ in adenoma and CRC                         Loss of Mucdhl                                      \[50-55\]
  Inversely associated with right side tumor, poorly differentiated type, advanced stage, poor prognosis, CIMP, MMR-deficient tumor   Induction of Wnt/β-catenin axis                                                                  
  *ALX4*                                                                                                                              ↓ in dysplasia and CRC                       Promoter hypermethylation                           \[59\]
  *PROX1*                                                                                                                             ↑ in CRC                                     Induction of β-catenin/TCF axis                     \[60,61\]
  Associated with advanced stage and lymph node metastasis                                                                            Inhibition of E-cadherin activity                                                                
  *HOXA4, D10*                                                                                                                        ↑ in CRC                                     Stem cell overpopulation and crypt renewal          \[63\]
  *HOXA5, A9, A10, C6*                                                                                                                Proximal colon tumor \> distal colon tumor   Not presented                                       \[64\]
  *HOXB13*                                                                                                                            Distal colon tumor \> proximal colon tumor   Not presented                                       \[64\]
  *HOXB7*                                                                                                                             ↑ in CRC                                     Activation of PI3K/Akt and MAPK pathways            \[67\]
  Associated with advanced stage, T stage, distant metastasis and poor OS                                                                                                                                                              

CRC: Colorectal cancer; TCF: β-catenin/T-cell factor; CIMP: CpG island methylation phenotype; OS: Overall survival; PI3K: Phosphatidylinositol-3 kinase; MAPK: Mitogen-activated protein kinase.

CONCLUSION
==========

Several homeobox genes are expressed aberrantly in various types of cancers, and the GI tract is no exception. Previous studies focused mainly on the roles of non-*HOX* genes, such as *CDX1* and *CDX2*, in GI cancers. Recently, several *HOX* genes have been investigated and shown to have specific roles in the development and invasion of GI cancers (Figure [1](#F1){ref-type="fig"}). However, intensive understanding of the underlying mechanisms including their transcriptional target genes, and co-factors or downstream effectors of homeobox genes in GI cancers are still lacking. Moreover, current knowledge of the homeobox genes in GI cancer could not reach the clinical efficacy of therapeutic targets or biomarkers, which need to be fulfilled in the future research.

![Schematic diagram of homeobox genes which have diverse effects on gastrointestinal cancers. Solid arrow indicates upregulated homeogox genes and dashed arrow indicates downregulated ones. Note that CDX2 shows tumor suppressive function in colorectal and esophageal squamous cell cancer whereas oncogenic effect on the formation of Barrett's esophagus and esophageal adenocarcinoma. HOXD10 also shows dual function, which has tumor suppressive effect on gastric cancer whereas oncogenic effect on colorectal cancer. BE: Barrett's esophagus; EAC: Esophageal adenocarcinoma; ESCC: Esophageal squamous cell carcinoma.](WJG-22-8247-g001){#F1}

Recent studies demonstrated the significant contribution of several *HOX* genes to chemoresistance. For example, downregulation of HOXA1 under regulation of HOTAIR or miR-100 enhance chemoresistance in pancreas cancer and small cell lung cancer\[[@B68],[@B69]\]. An improved understanding of the mechanism of this effect may reveal a means to create tailored, precision medicine of GI cancers. Meanwhile, the regulation of homeobox genes by several non-coding RNAs, including miRNAs, may provide a means to restore the aberrant expression of homeobox genes in GI cancers. Finally, the differential expression pattern of homeobox genes in various cancers may provide valuable information for the diagnosis of challenging cases of GI tumors.

Manuscript source: Invited manuscript

Specialty type: Gastroenterology and hepatology

Country of origin: South Korea

Peer-review report classification

Grade A (Excellent): A

Grade B (Very good): B, B

Grade C (Good): 0

Grade D (Fair): 0

Grade E (Poor): 0

Conflict-of-interest statement: None of the authors have potential conflicts (financial, professional, or personal) that are relevant to this publication.

Peer-review started: July 6, 2016

First decision: July 29, 2016

Article in press: August 23, 2016

P- Reviewer: Mocellin S, Tarnawski AS, Wargovich MJ S- Editor: Gong ZM L- Editor: A E- Editor: Wang CH

[^1]: Author contributions: Joo MK wrote the paper; Park JJ and Chun HJ revised the manuscript for critical intellectual content.

    Supported by the Korean College of Helicobacter and Upper Gastrointestinal Research Foundation Grant; and a Korea University Grant, No. K1512661.

    Correspondence to: Hoon Jai Chun, MD, PhD, AGAF, Division of Gastroenterology and Hepatology, Department of Internal Medicine, Institute of Digestive Disease and Nutrition, Korea University College of Medicine, 126-1, Anam-dong 5 ga, Seongbuk-gu, Seoul 02841, South Korea. <drchunhj@chol.com>

    Telephone: +82-2-9206555 Fax: +82-2-9531943
